Not to be outdone by Pfizer’s big announcement, Russia’s state-run Gamaleya Research Institute announced Wednesday that its Sputnik V vaccine is 92% effective.
Why it matters: Experts have criticized the lack of transparency around the vaccine and the haste with which the Kremlin approved it, but several countries are lining up to gain access.
- Hungary is the first EU country to announce a plan to buy it, per the FT. It expects a sample within the next week or so, and it's in “advanced negotiations” for a larger order.
- Russia has already sold doses to Brazil, India, Mexico and Egypt, per WSJ. It also plans to make the vaccine available to countries in its neighborhood, like Kazakhstan.
- The Philippines plans to join clinical trials for the vaccine, with President Rodrigo Duterte even saying he would be injected himself.
- Russia has discussed the distribution of its vaccine with a number of other countries, including Indonesia, Saudi Arabia and the UAE.
Yes, but: The rhetoric from Moscow has been far out in front of any evidence that the vaccine is safe, effective and can be developed at a sufficient scale to be distributed around the world.
The bottom line: “Why is Russia doing this? It’s the international vaccine race. They want to be seen to be keeping up with their competitors in other countries,” John Moore, a vaccine researcher at Cornell, told Science. “It’s clearly a rushed out announcement. But it doesn’t mean it’s wrong.”
Go deeper: EU purchases 200m doses of Pfizer's vaccine
